Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of WXFL10203614 in moderate-to-severe active rheumatoid arthritis
CTR20231901Phase 3Active
- Sponsor
- Wuxi Fuxin Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing WXFL10203614 with Placebo (2 arms). Primary endpoint: ACR20 response rate. Started Sep 2023; status: active.
02
Drugs
WXFL10203614
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20231901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231901.